What is GLP-1 therapy and how does it help with weight loss?

GLP-1 receptor agonists like semaglutide and tirzepatide reduce appetite and slow gastric emptying to support medically supervised weight loss. They require a prescription and provider evaluation — they are not appropriate for everyone.

How much does the medical weight loss program cost?

Programs start at $149/month — all-inclusive with no hidden fees and free shipping. Cost details are discussed during the provider consultation.

Does Sarasota Trim Clinic have a physical office?

No. Sarasota Trim Clinic is a telehealth service. There is no public walk-in office. Consultations, prescriptions, and medication delivery all happen remotely.

Is a prescription guaranteed after signing up?

No. Prescription medication is only provided when a licensed provider determines it is medically appropriate based on your individual health evaluation.

Semaglutide vs. Tirzepatide: What's the Difference?

The main difference is their mechanism: semaglutide targets one receptor (GLP-1), while tirzepatide targets two (GLP-1 and GIP). Both are effective for medical weight loss when supervised by a provider, but tirzepatide's dual action may offer enhanced metabolic results for some patients. Only a healthcare provider can determine which is right for you.

Discuss Options with a Provider

Understanding the Mechanisms

Semaglutide (Single Agonist)

Acts solely on the GLP-1 receptor. It mimics the hormone responsible for signaling the brain that you are full and slows down how quickly the stomach empties. It is highly studied and widely prescribed.

Tirzepatide (Dual Agonist)

Acts on both the GLP-1 and GIP receptors. This combined approach exerts a synergistic effect on appetite regulation and insulin sensitivity, often leading to distinct metabolic responses compared to single agonists.

FDA Approval & Compounding Status

Both medications have FDA-approved brand versions. Semaglutide is the active ingredient in Ozempic and Wegovy. Tirzepatide is the active ingredient in Mounjaro and Zepbound.

Crucially: Compounded versions of both semaglutide and tirzepatide are legally available during drug shortages, but neither compounded version is FDA-approved.

Side-by-Side Comparison

Feature	Semaglutide	Tirzepatide
Mechanism	GLP-1 receptor agonist	GLP-1 & GIP receptor agonist
FDA-Approved Brands	Ozempic, Wegovy, Rybelsus	Mounjaro, Zepbound
Compounded Status	Not FDA-Approved	Not FDA-Approved
Common Side Effects	Nausea, vomiting, diarrhea, constipation	Nausea, diarrhea, constipation, indigestion
Typical Starting Use Cases	First-line medical weight management intervention	Patients needing advanced metabolic support or those who plateau on GLP-1 alone

Which One Is Right For You?

Both medications have robust clinical trial data supporting their efficacy. While some trials suggest tirzepatide's dual mechanism may yield higher average weight reduction percentages, semaglutide remains the highly established gold standard.

Only a licensed healthcare provider can determine which medication is right for you.

Providers consider your personal tolerance to gastrointestinal side effects.
Providers review your history of weight loss plateauing.
Providers evaluate your specific comorbidities.

Important Medical Information

Both semaglutide and tirzepatide require a prescription and medical supervision. Neither is appropriate for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Both carry risks of gastrointestinal distress and rare serious conditions like pancreatitis. Always disclose your full medical history during consultation.

Deep Dive: Semaglutide →Deep Dive: Tirzepatide →Semaglutide in Sarasota →Tirzepatide in Sarasota →Check Your Eligibility →GLP-1 Safety Data →

Medical Disclaimer: The information provided on this page is for educational purposes only. It is not medical advice. Only a licensed healthcare provider can evaluate your health and determine if GLP-1 or GLP-1/GIP receptor agonists are appropriate.

MEDICAL SOURCES & FURTHER READING

These sources address the topics identified below. They provide general education, not individualized medical advice, a clinic endorsement or a prediction of your results. Prescription treatment requires evaluation by a licensed provider; eligibility, medication and dosing depend on individual circumstances.

U.S. Food and Drug Administration
Wegovy prescribing information and Medication Guide (PDF)
Semaglutide indications, mechanism, contraindications, thyroid warning, pancreatitis, pregnancy and adverse reactions; this label does not apply to compounded products.
U.S. Food and Drug Administration
Zepbound prescribing information and Medication Guide (PDF)
Tirzepatide indications, dual GIP/GLP-1 mechanism, contraindications and adverse reactions; this label does not apply to compounded products.
U.S. Food and Drug Administration
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Lack of FDA approval for compounded drugs, dosing errors, quality concerns and limits on compounding.

RESEARCH & REFERENCES

Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding, Rachel L. Batterham, Salvatore Calanna, et al.; STEP 1 Study Group · New England Journal of Medicine · 2021
Research published in the New England Journal of Medicine reported greater mean weight reduction with semaglutide plus lifestyle intervention than with placebo in the studied population. This was not a study of Sarasota Trim Clinic or compounded medication, and individual results vary.
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.; SURMOUNT-1 Investigators · New England Journal of Medicine · 2022
Research published in the New England Journal of Medicine reported weight reduction across the tirzepatide groups during a 72-week trial with lifestyle intervention. Results depended on the trial regimen and population, do not establish compounded-product equivalence, and are not a clinic outcome or a guarantee.